The PPP2R1B gene has recently been implicated as a tumor suppressor based on the ®nding of somatic alterations in lung and colon cancers. PPP2R1B is located on chromosome 11q22 ± 24 which coincides with the site of frequent loss of heterozygosity (LOH) in ovarian cancer. We investigated if the PPP2R1B gene was inactivated in ovarian cancer by single strand conformational polymorphism (SSCP) and heteroduplex (HD) analysis of 99% of the coding region. LOH at the PPP2R1B locus was detected in 32% of the malignant tumors but no somatic alterations were detected in any of 65 malignant, ®ve borderline or six benign tumors. A germline G4A transition (GGC4GAC) in codon 90 was detected in 4/76 tumors. This alteration has previously been described as a mutation but on further investigation we found that the frequency of this variant among 167 ovarian cancers (4.2%) was not statistically signi®cantly dierent from that observed in 247 noncancer random controls (2.4%). We conclude that the PPP2R1B gene is not involved in the pathogenesis of ovarian cancer. The codon 90 Gly4Asp alteration may represent a non-pathological polymorphism and consequently the mutation frequency reported in lung cancers may have been overstated and the designation of PPP2R1B as a tumor suppressor gene should be regarded with caution.
The PPP2R1B gene has recently been implicated as a tumor suppressor based on the ®nding of somatic alterations in lung and colon cancers. PPP2R1B is located on chromosome 11q22 ± 24 which coincides with the site of frequent loss of heterozygosity (LOH) in ovarian cancer. We investigated if the PPP2R1B gene was inactivated in ovarian cancer by single strand conformational polymorphism (SSCP) and heteroduplex (HD) analysis of 99% of the coding region. LOH at the PPP2R1B locus was detected in 32% of the malignant tumors but no somatic alterations were detected in any of 65 malignant, ®ve borderline or six benign tumors. A germline G4A transition (GGC4GAC) in codon 90 was detected in 4/76 tumors. This alteration has previously been described as a mutation but on further investigation we found that the frequency of this variant among 167 ovarian cancers (4.2%) was not statistically signi®cantly dierent from that observed in 247 noncancer random controls (2.4%). We conclude that theIntroduction Ovarian cancer is the leading cause of death among gynecological cancers yet relatively little is known about the somatic genetics of the disease. LOH analysis has provided good evidence for the involvement of many tumor suppressor genes (TSGs) in the development of ovarian cancer but apart from TP53 (Skomedal et al., 1997) and more recently PTEN (Obata et al., 1998) few have been shown to be inactivated in a signi®cant proportion of cases. LOH on chromosome 11q22 ± 24 has been one of the most consistent ®ndings in such studies (Monaco et al., 1997; Davis et al., 1996; Gabra et al., 1996) and the region is likely to harbor at least 2 important ovarian TSGs. Many other types of solid tumors show LOH on 11q22 ± 24 (Herbst et al., 1999; Evans et al., 1998; Murakami et al., 1998; Koreth et al., 1997; Hui et al., 1996) and there is a possibility that the same gene(s) may be involved in these cancers as well. Consequently any TSG identi®ed on 11q22 ± 24 in one tumor type must be considered a good candidate TSG for the other tumor types. Recently one such candidate, the b isoform of the structural/regulatory component of the serine/threonine protein phosphate 2A holoenzyme (PPP2R1B), has been shown to be somatically inactivated in a small proportion of lung and colon carcinomas (Wang et al., 1998b) . In this study we examined the PPP2R1B gene for somatic alterations and for LOH at the PPP2R1B locus in 76 malignant, borderline and benign epithelial ovarian tumors.
Results
LOH was assessed using microsatellite markers D11S35 and D11S1647 which¯ank the centromeric side of PPP2R1B, and markers D11S1987 and D11S938 which ank the telomeric side. The LOH frequencies are summarized in Table 1 . Among the malignant tumors 32% showed LOH with at least one of the closest anking markers (D11S1647 and D11S1987) or showed a pattern of LOH with the outside markers consistent with LOH across the PPP2R1B locus. The highest frequency of LOH was detected in the serous (42%) and unclassi®ed adenocarcinomas (40%) and no LOH was detected in any of the mucinous carcinomas. Only one of the ®ve borderline and none of the six benign tumors showed LOH with any of the four markers used.
Seventy-six tumors were analysed by SSCP/HD for mutations in exons 1 ± 14 of the PPP2R1B gene regardless of LOH status. No aberrant band shifts were detected apart from four tumors which showed identical band shifts in exon 3. Sequencing of these cases showed that all harbored a G4A transition (GGC4GAC) in codon 90 which results in a glycine (Gly) to aspartic acid (Asp) substitution. Comparison with the matching normal DNA showed that these represented germline alterations (Figure 1 ). In order to more accurately assess the frequency of this variant, lymphocyte DNA was analysed from an additional 91 epithelial ovarian cancer patients. This identi®ed a further three cases bringing the total number of ovarian cancers with this variant to 7/167 (4.2%). The relevant clinical and histological features of these ovarian cancers are shown in Table 2 . The variant was present in all histological sub-types and in both low and high grade and early and late stage tumors. In the four tumors where LOH analysis was possible, three showed LOH across the PPP2R1B locus and in each of these cases it was the common glycine (GGC) allele that was lost.
As a means of assessing if the codon 90 Gly to Asp variant represented a germline pathological mutation or a rare polymorphism we analysed for this variant in DNA from 247 female random non-cancer controls. The aspartic acid variant was detected in 6/247 (2.4%) controls which was not statistically signi®cantly dierent from the frequency among the ovarian tumors (P=0.39), even when the benign and borderline tumors were excluded (P=0.38).
Discussion
There is compelling evidence that chromosome 11q harbors a TSG(s) involved in the development of a wide variety of solid malignancies but to date identifying the actual gene(s) has proved to be an elusive goal. LOH studies have identi®ed several small common regions of LOH but screening of candidate genes encoded in these regions has not positively identi®ed any as being bona ®de TSGs (Monaco et al., 1997; . Recently Wang et al. (1998b) identi®ed the PPP2R1B gene from a region on 11q22 ± 24 commonly deleted in lung cancers and was able to demonstrate somatic alterations in a small proportion of primary lung cancers and lung cancer cell lines as well as in some primary colon cancers. This locus is frequently deleted in a wide range of solid tumors which raises the possibility that PPP2R1B might be the target of the LOH in all of these tumors.
We have reported previously a high frequency of LOH in ovarian cancer on 11q22 ± 24 (Davis et al., 1996) . In this study using microsatellite markers anking the PPP2R1B locus we have con®rmed that LOH of the PPP2R1B locus is common with over 40% of serous ovarian cancers showing LOH. However within the limits of this study we did not ®nd evidence for LOH restricted to the PPP2R1B locus and our unpublished data for these tumors suggests that in the majority of cases the LOH involves the whole 11q arm. Our failure to identify any somatic alteration among our large cohort of ovarian tumors, 29% of which showed LOH across the PPP2R1B locus, argues against PPP2R1B having a tumor suppressor function in ovarian cancer. However the detection of the codon 90 Gly to Asp variant in 7/167 ovarian tumors which had previously been proposed to represent a mutation was at odds with the absence of any somatic alterations. In the four cases where matching tumor and normal DNA was available, one showed retention of both alleles while the other three showed loss of the common Gly allele and retention of the variant Asp allele. This would be the result predicted if the Asp variant represented a germline mutation but in fact the frequency of the variant among 247 non-cancer controls was not signi®cantly dierent from the ovarian cancer group and is therefore very likely to represent a non-pathological variant.
If the codon 90 Asp variant indeed represents a polymorphism then the already low frequency of mutations detected in lung cancer by Wang et al. (1998b) is reduced from 5/33 (15%) among primary cancers to 3/33 (9%) and from 4/70 (6%) lung cancer cell lines to 3/70 (4%). Many genes may show a low frequency of mutation in tumors because of generalized and/or D11S1987. The tumor genotype with respect to the Gly/Asp variant was based on the intensity of the variant and normal alleles in the SSCP/HD gels. het=heterozygous with both D11S1647 and D11S1987; loh=loss of heterozygosity with either D11S1647 or D11S1987; nd=not done because tumor DNA was unavailable; na=grade and stage data was not available; Gly=glycine; Asp=aspartic acid genomic instability which are unrelated to a role in tumorigenesis. Therefore the designation of a gene as a tumor suppressor based solely on a low frequency of mutations must remain tentative until other evidence can substantiate a tumor suppressor function. The fact that the codon 90 Gly to Asp polymorphism was detected as a somatic alteration in two primary lung tumors raises the possibility that some of the other somatic alterations reported by Wang et al. may also be of no pathological relevance. Many of the alterations identi®ed in the lung and colon cancers were deletions of one or more exons and it is possible that some of these may be due to the reliance on RT ± PCR generated products which are likely to be more prone to splicing artifacts reminiscent of those that led to controversial assignment of the FHIT and TSG101 genes as tumor suppressors (Gayther et al., 1997; Wang et al., 1998b) . The protein phosphatase 2A holoenzyme is a trimeric molecule and can exist in multiple isoforms. Therefore it is possible that the low frequency of mutations detected by Wang et al. is simply a re¯ection of the fact that PPP2R1B is just one of the many components whose mutation could abrogate the function of the PP2A holoenzyme. Clari®cation of the status of the PPP2R1B gene in the etiology of lung and colon cancers must await the results of independent studies but it seems clear from our data that the PPP2R1B gene is of no relevance in ovarian tumorigenesis.
Materials and methods
Tumor specimens and random control DNA Epithelial ovarian tumors were obtained with the consent of women undergoing surgery for primary epithelial ovarian cancer. Matching tumor and normal DNA was extracted from fresh tumor biopsies and from blood lymphocytes as described previously (Davis et al., 1996) . The collection included 38 serous tumors (33 malignant, two borderline and three benign), 16 mucinous tumors (ten malignant, three borderline and three benign), 17 endometrioid carcinomas and ®ve unclassi®ed adenocarcinomas. In addition lymphocyte DNA only was collected from a further 91 women with epithelial ovarian cancer. DNA was extracted from lymphocytes from 247 healthy white Caucasian female volunteers also from southern England.
PCR and LOH analysis
PCR was carried out using 10 ± 100 ng of genomic DNA in a reaction volume of 10 m et al with the inclusion of 1 mCi of (a-32 P)dCTP. Four microsatellite markers (D110S35, D10S1647, D11S1987 and D11S938)¯anking the PPP2R1B locus were used to assess LOH. The alleles were separated on 6% denaturing polyacrylamide gels and examined following autoradiographic exposure. Assessment of LOH was based on visual comparison of the intensities of the normal DNA alleles and those of the tumor.
SSCP and HD mutation analysis of PPP2R1B Exons 1 ± 14 of the PPP2R1B gene, which represent 99% of the coding sequence, were ampli®ed separately using¯anking intronic primers described by Baysal et al. 1998) . PCR products were denatured by addition of an equal volume of 95% formamide and heating to 958C for 5 min followed by rapid cooling on ice. Denatured products were subject to SSCP/HD analysis by electrophoresis through 0.56MDE gel matrix (Flowgen, UK) as well as 6% polyacrylamide gels containing 5% glycerol (Campbell et al., 1994) . Cases showing aberrant band shifts were re-ampli®ed and the PCR product puri®ed on a Wizard PCR prep column (Promega, UK) and directly sequenced using the Thermosequenase kit (Amersham, UK). Matching normal DNA was also sequenced to assess if the alteration was germline or somatic.
Statistical analysis
The two-sided Fisher's exact test was used to compare the frequency of PPP2R1B polymorphisms among cancer and control individuals.
